AI assistant
ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2016
Mar 16, 2016
33882_dirs_2016-03-16_64f59c84-98b5-48ea-8eac-56472641e076.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2016-03-14
Reporting Person: Cormack Scott Daniel (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-03-14 | Common Stock | M | 25000 | $0.00 | Acquired | 136942 | Direct |
| 2016-03-15 | Common Stock | S | 12033 | $0.83 | Disposed | 124909 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-03-14 | Restricted Stock Unit (RSU) | $ | M | 4687 | Disposed | 2016-04-13 | Common Stock (4687) | Direct |
| 2016-03-14 | Restricted Stock Unit (RSU) | $ | M | 4688 | Disposed | 2017-01-31 | Common Stock (4688) | Direct |
| 2016-03-14 | Restricted Stock Unit (RSU) | $ | M | 6250 | Disposed | 2018-04-13 | Common Stock (6250) | Direct |
| 2016-03-14 | Restricted Stock Unit (RSU) | $ | M | 9375 | Disposed | 2019-06-18 | Common Stock (9375) | Direct |
| 2016-03-14 | Stock Option (right to buy) | $0.85 | A | 300000 | Acquired | 2026-03-14 | Common Stock (300000) | Direct |
| 2016-03-14 | Stock Option (right to buy) | $0.85 | A | 135000 | Acquired | 2026-03-14 | Common Stock (135000) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 68743 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $7.25 | 2016-05-12 | Common Stock (4130) | 4130 | Indirect |
| Stock Option (right to buy) | $14.20 | 2020-06-08 | Common Stock (1750) | 1750 | Indirect |
| Stock Option (right to buy) | $16.83 | 2021-01-03 | Common Stock (28820) | 28820 | Indirect |
| Stock Option (right to buy) | $13.00 | 2022-05-08 | Common Stock (14362) | 14362 | Indirect |
| Stock Option (right to buy) | $11.95 | 2023-03-12 | Common Stock (20000) | 20000 | Indirect |
| Restricted Stock Unit | $ | 2017-01-31 | Common Stock (2500) | 2500 | Indirect |
| Stock Option (right to buy) | $11.79 | 2024-03-14 | Common Stock (25000) | 25000 | Indirect |
| Restricted Stock Unit (RSU) | $ | 2018-04-13 | Common Stock (6250) | 6250 | Indirect |
| Restricted Stock Unit (right to buy) | $ | Common Stock (5000) | 5000 | Indirect | |
| Restricted Stock Unit (RSU) | $ | Common Stock (15000) | 15000 | Indirect | |
| Stock Option (right to buy) | $1.86 | 2025-05-19 | Common Stock (37500) | 37500 | Indirect |
| Restricted Stock Unit (RSU) | $ | 2019-06-18 | Common Stock (14062) | 14062 | Indirect |
Footnotes
F1: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
F2: Represents shares of common stock that have been sold by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
F3: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
F4: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest on the later of: (i) each anniversary of January 1, 2012; and (ii) the first day thereafter during which the issuer's trading window is open.
F5: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2013; and (ii) the first day thereafter during which the issuer's trading window is open.
F6: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2014; and (ii) the first day thereafter during which the issuer's trading window is open.
F7: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of January 1, 2015; and (ii) the first day thereafter during which the issuer's trading window is open.
F8: Pursuant to the terms of the options, 50% of the total shares underlying the option vest on the achievement of certain milestones, and 50% vest in monthly installments over 24 months commencing one month from achievement of one of the milestones. The options will lapse in full if achievement of one of the milestones is not met on or before December 31, 2016.
F9: The options were fully vested on May 12, 2010.
F10: The options were fully vested on May 26, 2011.
F11: The options were fully vested on January 3, 2015.
F12: The options were fully vested on January 1, 2016.
F13: The options vest in monthly installments over 48 months commencing one month from January 1, 2013.
F14: The options vest in monthly installments over 48 months commencing one month from January 1, 2014.
F15: Pursuant to the terms of the RSU, 100% of the total shares underlying the RSU vest on the later of (i) release of positive data from a clinical trial, and (ii) the first trading day thereafter on which the issuer's trading window is open.
F16: The RSUs expire 30 days from the date they vest.
F17: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of June 12, 2014 and (ii) the first day thereafter during which the issuer's trading window is open.
F18: The options vest in monthly installments over 48 months commencing one month from January 1, 2015.